Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: A propensity score-matched analysis

Kang Yin Chen, Seung-Woon Rha, Lin Wang, Yong Jian Li, Guang Ping Li, Kanhaiya L. Poddar, Ji Young Park, Cheol Ung Choi, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong, Young Keun Ahn, Taek Jong Hong, Young Jo Kim, Seung Ho Hur, In Whan Seong, Jei Keon Chae, Myeong Chan Cho, Jang Ho BaeDong Hoon Choi, Yang Soo Jang, In Ho Chae, Chong Jin Kim, Jung Han Yoon, Wook Sung Chung, Ki Bae Seung, Seung Jung Park

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: This study sought to compare everolimus-eluting stents (EES) with zotarolimus-eluting stents (ZES) in patients with acute myocardial infarction (AMI). Background: There is a paucity of data to exclusively evaluate the safety and efficacy of second-generation drug-eluting stents (DES) in the setting of AMI. Methods: The present study enrolled 3,309 AMI patients treated with ZES (n = 1,608) or EES (n = 1,701) in a large-scale, prospective, multicenter registry - KAMIR (Korea Acute Myocardial Infarction Registry). Propensity score matching was applied to adjust for differences in baseline clinical and angiographic characteristics, producing a total of 2,646 patients (1,343 receiving ZES, and 1,343 receiving EES). Target lesion failure (TLF) was defined as the composite of cardiac death, recurrent nonfatal myocardial infarction, or target lesion revascularization. Major clinical outcomes at 1 year were compared between the 2 propensity score-matched groups. Results: After propensity score matching, baseline clinical and angiographic characteristics were similar between the 2 groups. Clinical outcomes of the propensity score-matched patients showed that, despite similar incidences of recurrent nonfatal myocardial infarction and in-hospital and 1-year mortality, patients in the EES group had significantly lower rates of TLF (6.5% vs. 8.7%, p = 0.029) and probable or definite stent thrombosis (0.3% vs. 1.6%, p < 0.001), compared with those in the ZES group. Furthermore, there was a numerically lower rate of target lesion revascularization (1.2% vs. 2.2%, p = 0.051) in the EES group than in the ZES group. Conclusions: In this propensity-matched comparison, EES seems to be superior to ZES in reducing TLF and stent thrombosis in patients with AMI.

Original languageEnglish
Pages (from-to)936-945
Number of pages10
JournalJACC: Cardiovascular Interventions
Volume5
Issue number9
DOIs
Publication statusPublished - 2012 Sep 1

Fingerprint

Propensity Score
Drug-Eluting Stents
Stents
Myocardial Infarction
Registries
Thrombosis
Korea
Everolimus
zotarolimus

Keywords

  • acute myocardial infarction
  • everolimus-eluting stents
  • percutaneous coronary intervention
  • zotarolimus-eluting stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction : A propensity score-matched analysis. / Chen, Kang Yin; Rha, Seung-Woon; Wang, Lin; Li, Yong Jian; Li, Guang Ping; Poddar, Kanhaiya L.; Park, Ji Young; Choi, Cheol Ung; Park, Chang Gyu; Seo, Hong Seog; Oh, Dong Joo; Jeong, Myung Ho; Ahn, Young Keun; Hong, Taek Jong; Kim, Young Jo; Hur, Seung Ho; Seong, In Whan; Chae, Jei Keon; Cho, Myeong Chan; Bae, Jang Ho; Choi, Dong Hoon; Jang, Yang Soo; Chae, In Ho; Kim, Chong Jin; Yoon, Jung Han; Chung, Wook Sung; Seung, Ki Bae; Park, Seung Jung.

In: JACC: Cardiovascular Interventions, Vol. 5, No. 9, 01.09.2012, p. 936-945.

Research output: Contribution to journalArticle

Chen, KY, Rha, S-W, Wang, L, Li, YJ, Li, GP, Poddar, KL, Park, JY, Choi, CU, Park, CG, Seo, HS, Oh, DJ, Jeong, MH, Ahn, YK, Hong, TJ, Kim, YJ, Hur, SH, Seong, IW, Chae, JK, Cho, MC, Bae, JH, Choi, DH, Jang, YS, Chae, IH, Kim, CJ, Yoon, JH, Chung, WS, Seung, KB & Park, SJ 2012, 'Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: A propensity score-matched analysis', JACC: Cardiovascular Interventions, vol. 5, no. 9, pp. 936-945. https://doi.org/10.1016/j.jcin.2012.05.009
Chen, Kang Yin ; Rha, Seung-Woon ; Wang, Lin ; Li, Yong Jian ; Li, Guang Ping ; Poddar, Kanhaiya L. ; Park, Ji Young ; Choi, Cheol Ung ; Park, Chang Gyu ; Seo, Hong Seog ; Oh, Dong Joo ; Jeong, Myung Ho ; Ahn, Young Keun ; Hong, Taek Jong ; Kim, Young Jo ; Hur, Seung Ho ; Seong, In Whan ; Chae, Jei Keon ; Cho, Myeong Chan ; Bae, Jang Ho ; Choi, Dong Hoon ; Jang, Yang Soo ; Chae, In Ho ; Kim, Chong Jin ; Yoon, Jung Han ; Chung, Wook Sung ; Seung, Ki Bae ; Park, Seung Jung. / Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction : A propensity score-matched analysis. In: JACC: Cardiovascular Interventions. 2012 ; Vol. 5, No. 9. pp. 936-945.
@article{eac3992468d443ca96ab4771d2c41e7e,
title = "Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: A propensity score-matched analysis",
abstract = "Objectives: This study sought to compare everolimus-eluting stents (EES) with zotarolimus-eluting stents (ZES) in patients with acute myocardial infarction (AMI). Background: There is a paucity of data to exclusively evaluate the safety and efficacy of second-generation drug-eluting stents (DES) in the setting of AMI. Methods: The present study enrolled 3,309 AMI patients treated with ZES (n = 1,608) or EES (n = 1,701) in a large-scale, prospective, multicenter registry - KAMIR (Korea Acute Myocardial Infarction Registry). Propensity score matching was applied to adjust for differences in baseline clinical and angiographic characteristics, producing a total of 2,646 patients (1,343 receiving ZES, and 1,343 receiving EES). Target lesion failure (TLF) was defined as the composite of cardiac death, recurrent nonfatal myocardial infarction, or target lesion revascularization. Major clinical outcomes at 1 year were compared between the 2 propensity score-matched groups. Results: After propensity score matching, baseline clinical and angiographic characteristics were similar between the 2 groups. Clinical outcomes of the propensity score-matched patients showed that, despite similar incidences of recurrent nonfatal myocardial infarction and in-hospital and 1-year mortality, patients in the EES group had significantly lower rates of TLF (6.5{\%} vs. 8.7{\%}, p = 0.029) and probable or definite stent thrombosis (0.3{\%} vs. 1.6{\%}, p < 0.001), compared with those in the ZES group. Furthermore, there was a numerically lower rate of target lesion revascularization (1.2{\%} vs. 2.2{\%}, p = 0.051) in the EES group than in the ZES group. Conclusions: In this propensity-matched comparison, EES seems to be superior to ZES in reducing TLF and stent thrombosis in patients with AMI.",
keywords = "acute myocardial infarction, everolimus-eluting stents, percutaneous coronary intervention, zotarolimus-eluting stents",
author = "Chen, {Kang Yin} and Seung-Woon Rha and Lin Wang and Li, {Yong Jian} and Li, {Guang Ping} and Poddar, {Kanhaiya L.} and Park, {Ji Young} and Choi, {Cheol Ung} and Park, {Chang Gyu} and Seo, {Hong Seog} and Oh, {Dong Joo} and Jeong, {Myung Ho} and Ahn, {Young Keun} and Hong, {Taek Jong} and Kim, {Young Jo} and Hur, {Seung Ho} and Seong, {In Whan} and Chae, {Jei Keon} and Cho, {Myeong Chan} and Bae, {Jang Ho} and Choi, {Dong Hoon} and Jang, {Yang Soo} and Chae, {In Ho} and Kim, {Chong Jin} and Yoon, {Jung Han} and Chung, {Wook Sung} and Seung, {Ki Bae} and Park, {Seung Jung}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.jcin.2012.05.009",
language = "English",
volume = "5",
pages = "936--945",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction

T2 - A propensity score-matched analysis

AU - Chen, Kang Yin

AU - Rha, Seung-Woon

AU - Wang, Lin

AU - Li, Yong Jian

AU - Li, Guang Ping

AU - Poddar, Kanhaiya L.

AU - Park, Ji Young

AU - Choi, Cheol Ung

AU - Park, Chang Gyu

AU - Seo, Hong Seog

AU - Oh, Dong Joo

AU - Jeong, Myung Ho

AU - Ahn, Young Keun

AU - Hong, Taek Jong

AU - Kim, Young Jo

AU - Hur, Seung Ho

AU - Seong, In Whan

AU - Chae, Jei Keon

AU - Cho, Myeong Chan

AU - Bae, Jang Ho

AU - Choi, Dong Hoon

AU - Jang, Yang Soo

AU - Chae, In Ho

AU - Kim, Chong Jin

AU - Yoon, Jung Han

AU - Chung, Wook Sung

AU - Seung, Ki Bae

AU - Park, Seung Jung

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Objectives: This study sought to compare everolimus-eluting stents (EES) with zotarolimus-eluting stents (ZES) in patients with acute myocardial infarction (AMI). Background: There is a paucity of data to exclusively evaluate the safety and efficacy of second-generation drug-eluting stents (DES) in the setting of AMI. Methods: The present study enrolled 3,309 AMI patients treated with ZES (n = 1,608) or EES (n = 1,701) in a large-scale, prospective, multicenter registry - KAMIR (Korea Acute Myocardial Infarction Registry). Propensity score matching was applied to adjust for differences in baseline clinical and angiographic characteristics, producing a total of 2,646 patients (1,343 receiving ZES, and 1,343 receiving EES). Target lesion failure (TLF) was defined as the composite of cardiac death, recurrent nonfatal myocardial infarction, or target lesion revascularization. Major clinical outcomes at 1 year were compared between the 2 propensity score-matched groups. Results: After propensity score matching, baseline clinical and angiographic characteristics were similar between the 2 groups. Clinical outcomes of the propensity score-matched patients showed that, despite similar incidences of recurrent nonfatal myocardial infarction and in-hospital and 1-year mortality, patients in the EES group had significantly lower rates of TLF (6.5% vs. 8.7%, p = 0.029) and probable or definite stent thrombosis (0.3% vs. 1.6%, p < 0.001), compared with those in the ZES group. Furthermore, there was a numerically lower rate of target lesion revascularization (1.2% vs. 2.2%, p = 0.051) in the EES group than in the ZES group. Conclusions: In this propensity-matched comparison, EES seems to be superior to ZES in reducing TLF and stent thrombosis in patients with AMI.

AB - Objectives: This study sought to compare everolimus-eluting stents (EES) with zotarolimus-eluting stents (ZES) in patients with acute myocardial infarction (AMI). Background: There is a paucity of data to exclusively evaluate the safety and efficacy of second-generation drug-eluting stents (DES) in the setting of AMI. Methods: The present study enrolled 3,309 AMI patients treated with ZES (n = 1,608) or EES (n = 1,701) in a large-scale, prospective, multicenter registry - KAMIR (Korea Acute Myocardial Infarction Registry). Propensity score matching was applied to adjust for differences in baseline clinical and angiographic characteristics, producing a total of 2,646 patients (1,343 receiving ZES, and 1,343 receiving EES). Target lesion failure (TLF) was defined as the composite of cardiac death, recurrent nonfatal myocardial infarction, or target lesion revascularization. Major clinical outcomes at 1 year were compared between the 2 propensity score-matched groups. Results: After propensity score matching, baseline clinical and angiographic characteristics were similar between the 2 groups. Clinical outcomes of the propensity score-matched patients showed that, despite similar incidences of recurrent nonfatal myocardial infarction and in-hospital and 1-year mortality, patients in the EES group had significantly lower rates of TLF (6.5% vs. 8.7%, p = 0.029) and probable or definite stent thrombosis (0.3% vs. 1.6%, p < 0.001), compared with those in the ZES group. Furthermore, there was a numerically lower rate of target lesion revascularization (1.2% vs. 2.2%, p = 0.051) in the EES group than in the ZES group. Conclusions: In this propensity-matched comparison, EES seems to be superior to ZES in reducing TLF and stent thrombosis in patients with AMI.

KW - acute myocardial infarction

KW - everolimus-eluting stents

KW - percutaneous coronary intervention

KW - zotarolimus-eluting stents

UR - http://www.scopus.com/inward/record.url?scp=84866376186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866376186&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2012.05.009

DO - 10.1016/j.jcin.2012.05.009

M3 - Article

C2 - 22995881

AN - SCOPUS:84866376186

VL - 5

SP - 936

EP - 945

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 9

ER -